首页 > 最新文献

American journal of nuclear medicine and molecular imaging最新文献

英文 中文
In vitro evaluation of PET radiotracers for imaging synaptic density, the acetylcholine transporter, AMPA-tarp-γ8 and muscarinic M4 receptors in Alzheimer's disease. 用于阿尔茨海默病突触密度、乙酰胆碱转运体、AMPA-tarp-γ8 和毒蕈碱 M4 受体成像的 PET 放射性同位素体外评估。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Faustine d'Orchymont, Andrea Narvaez, Roger Raymond, Pallavi Sachdev, Arnaud Charil, Stephen Krause, Neil Vasdev

Several therapeutics and biomarkers that target Alzheimer's disease (AD) are under development. Our clinical positron emission tomography (PET) research programs are interested in six radiopharmaceuticals to image patients with AD and related dementias, specifically [11C]UCB-J and [18F]SynVesT-1 for synaptic vesicle glycoprotein 2A as a marker of synaptic density, two vesicular acetylcholine transporter PET radiotracers: [18F]FEOBV and [18F]VAT, as well as the transmembrane AMPA receptor regulatory protein (TARP)-γ8 tracer, [18F]JNJ-64511070, and the muscarinic acetylcholine receptor (mAChR) M4 tracer [11C]MK-6884. The goal of this study was to compare all six radiotracers (labeled with tritium or 18F) by measuring their density variability in pathologically diagnosed cases of AD, mild cognitive impairment (MCI) and normal healthy volunteer (NHV) human brains, using thin-section in vitro autoradiography (ARG). Region of interest analysis was used to quantify radioligand binding density and determine whether the radioligands provide a signal-to-noise ratio optimal for showing changes in binding. Our preliminary study confirmed that all six radiotracers show specific binding in MCI and AD. An expected decrease in their respective target density in human AD hippocampus tissues compared to NHV was observed with [3H]UCB-J, [3H]SynVesT-1, [3H]JNJ-64511070, and [3H]MK-6884. This preliminary study will be used to guide human PET imaging of SV2A, TARP-γ8 and the mAChR M4 subtype for imaging in AD and related dementias.

目前正在开发几种针对阿尔茨海默病(AD)的治疗药物和生物标记物。我们的临床正电子发射断层扫描(PET)研究项目对六种放射性药物很感兴趣,这些药物可用于对阿尔茨海默病和相关痴呆症患者进行成像,特别是用于突触囊泡糖蛋白 2A 的[11C]UCB-J 和[18F]SynVesT-1(作为突触密度的标记)、两种囊泡乙酰胆碱转运体 PET 放射性racers:[18F]FEOBV和[18F]VAT,以及跨膜AMPA受体调节蛋白(TARP)-γ8示踪剂[18F]JNJ-64511070和毒蕈碱乙酰胆碱受体(mAChR)M4示踪剂[11C]MK-6884。本研究的目的是利用薄片体外自显影(ARG)技术,通过测量病理诊断的 AD、轻度认知障碍(MCI)和正常健康志愿者(NHV)人脑中这六种放射性掺杂剂(用氚或 18F 标记)的密度变化,对它们进行比较。感兴趣区分析用于量化放射性配体的结合密度,并确定放射性配体是否能提供显示结合变化的最佳信噪比。我们的初步研究证实,所有六种放射性配体在 MCI 和 AD 中都有特异性结合。与NHV相比,[3H]UCB-J、[3H]SynVesT-1、[3H]JNJ-64511070和[3H]MK-6884在人类AD海马组织中的各自靶密度出现了预期的下降。这项初步研究将用于指导对 SV2A、TARP-γ8 和 mAChR M4 亚型进行人体 PET 成像,以对注意力缺失症和相关痴呆症进行成像。
{"title":"In vitro evaluation of PET radiotracers for imaging synaptic density, the acetylcholine transporter, AMPA-tarp-γ8 and muscarinic M4 receptors in Alzheimer's disease.","authors":"Faustine d'Orchymont, Andrea Narvaez, Roger Raymond, Pallavi Sachdev, Arnaud Charil, Stephen Krause, Neil Vasdev","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several therapeutics and biomarkers that target Alzheimer's disease (AD) are under development. Our clinical positron emission tomography (PET) research programs are interested in six radiopharmaceuticals to image patients with AD and related dementias, specifically [<sup>11</sup>C]UCB-J and [<sup>18</sup>F]SynVesT-1 for synaptic vesicle glycoprotein 2A as a marker of synaptic density, two vesicular acetylcholine transporter PET radiotracers: [<sup>18</sup>F]FEOBV and [<sup>18</sup>F]VAT, as well as the transmembrane AMPA receptor regulatory protein (TARP)-γ8 tracer, [<sup>18</sup>F]JNJ-64511070, and the muscarinic acetylcholine receptor (mAChR) M4 tracer [<sup>11</sup>C]MK-6884. The goal of this study was to compare all six radiotracers (labeled with tritium or <sup>18</sup>F) by measuring their density variability in pathologically diagnosed cases of AD, mild cognitive impairment (MCI) and normal healthy volunteer (NHV) human brains, using thin-section <i>in vitro</i> autoradiography (ARG). Region of interest analysis was used to quantify radioligand binding density and determine whether the radioligands provide a signal-to-noise ratio optimal for showing changes in binding. Our preliminary study confirmed that all six radiotracers show specific binding in MCI and AD. An expected decrease in their respective target density in human AD hippocampus tissues compared to NHV was observed with [<sup>3</sup>H]UCB-J, [<sup>3</sup>H]SynVesT-1, [<sup>3</sup>H]JNJ-64511070, and [<sup>3</sup>H]MK-6884. This preliminary study will be used to guide human PET imaging of SV2A, TARP-γ8 and the mAChR M4 subtype for imaging in AD and related dementias.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis. 聚(ADP-核糖)聚合酶(PARP)靶向 PET 成像在非肿瘤学中的应用:非酒精性脂肪性肝炎临床前模型的试验研究。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Troels E Jeppesen, Tuo Shao, Jiahui Chen, Jimmy S Patel, Xin Zhou, Andreas Kjaer, Steven H Liang

Poly(ADP-ribose) polymerase (PARP) activation often indicates a disruptive signal to lipid metabolism, the physiological alteration of which may be implicated in the development of non-alcoholic fatty liver disease. The objective of this study was to evaluate the capability of [68Ga]DOTA-PARPi PET to detect hepatic PARP expression in a non-alcoholic steatohepatitis (NASH) mouse model. In this study, male C57BL/6 mice were subjected to a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for a 12-week period to establish preclinical NASH models. [68Ga]DOTA-PARPi PET imaging of the liver was conducted at the 12-week mark after CDAHFD feeding. Comprehensive histopathological analysis, covering hepatic steatosis, inflammation, fibrosis, along with blood biochemistry, was performed in both NASH models and control groups. Despite the induction of severe inflammation, steatosis and fibrosis in the liver of mice with the CDAHFD-NASH model, PET imaging of NASH with [68Ga]-DOTA-PARPi did not reveal a significantly higher uptake in NASH models compared to the control. This underscores the necessity for further development of new chelator-based PARP1 tracers with high binding affinity to enable the visualization of PARP1 changes in NASH pathology.

多聚(ADP-核糖)聚合酶(PARP)的活化通常预示着脂质代谢的破坏信号,其生理改变可能与非酒精性脂肪肝的发生有关。本研究旨在评估[68Ga]DOTA-PARPi PET在非酒精性脂肪性肝炎(NASH)小鼠模型中检测肝脏PARP表达的能力。在这项研究中,雄性 C57BL/6 小鼠接受了为期 12 周的胆碱缺乏、L-氨基酸定义的高脂肪饮食(CDAHFD),以建立临床前 NASH 模型。喂食CDAHFD 12周后,对肝脏进行[68Ga]DOTA-PARPi PET成像。对 NASH 模型和对照组进行了全面的组织病理学分析,包括肝脏脂肪变性、炎症、纤维化以及血液生化。尽管CDAHFD-NASH模型诱导了小鼠肝脏的严重炎症、脂肪变性和纤维化,但用[68Ga]-DOTA-PARPi对NASH进行正电子发射计算机断层成像时,NASH模型的摄取量并未明显高于对照组。这凸显了进一步开发基于螯合剂的新型 PARP1 示踪剂的必要性,这种示踪剂具有很高的结合亲和力,可使 PARP1 在 NASH 病理学中的变化可视化。
{"title":"Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis.","authors":"Troels E Jeppesen, Tuo Shao, Jiahui Chen, Jimmy S Patel, Xin Zhou, Andreas Kjaer, Steven H Liang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Poly(ADP-ribose) polymerase (PARP) activation often indicates a disruptive signal to lipid metabolism, the physiological alteration of which may be implicated in the development of non-alcoholic fatty liver disease. The objective of this study was to evaluate the capability of [<sup>68</sup>Ga]DOTA-PARPi PET to detect hepatic PARP expression in a non-alcoholic steatohepatitis (NASH) mouse model. In this study, male C57BL/6 mice were subjected to a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for a 12-week period to establish preclinical NASH models. [<sup>68</sup>Ga]DOTA-PARPi PET imaging of the liver was conducted at the 12-week mark after CDAHFD feeding. Comprehensive histopathological analysis, covering hepatic steatosis, inflammation, fibrosis, along with blood biochemistry, was performed in both NASH models and control groups. Despite the induction of severe inflammation, steatosis and fibrosis in the liver of mice with the CDAHFD-NASH model, PET imaging of NASH with [<sup>68</sup>Ga]-DOTA-PARPi did not reveal a significantly higher uptake in NASH models compared to the control. This underscores the necessity for further development of new chelator-based PARP1 tracers with high binding affinity to enable the visualization of PARP1 changes in NASH pathology.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by 68Ga-FAPI PET/MR scan. 病例报告:68Ga-FAPI PET/MR 扫描辅助诊断和治疗晚期高级别浆液性卵巢癌。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Mengna Zhu, Si Sun, Lin Huang, Mengqing Chen, Jing Cai, Zehua Wang, Liqiong Cai

High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer with insidious onset, rapid growth, and invasive spread. Here, we reported the diagnosis and treatment of a 53-year-old patient with a history of hysterectomy aided by the 68Ga-FAPI PET/MR scan. The patient was first presented to the local hospital with a lump on the left side of the neck with a biopsy suggesting metastatic cancer. Pelvic ultrasonography revealed two irregular masses. After admission, tumor markers, pathology consultation of the biopsy, and the 68Ga-FAPI PET/MR scan were administered. The biopsy of the lump suggested poorly differentiated adenocarcinoma and CA125 was elevated at 530.6 U/ml. The 68Ga-FAPI PET/MR scan showed several abnormal lymph nodes and two soft tissue masses with borders of dispersed restriction displaying internally uneven signals depicted by slightly elongated T1 and T2 signals within the pelvic cavity suggesting that pelvic mass could be the primary lesion. The patient received cytoreductive surgery including bilateral adnexectomy, omentectomy, and appendectomy. Post-surgical pathology suggested left and right HGSOC with left fallopian tube invasion. The patient completed six courses of first-line chemotherapy and remained progression-free for 14 months up to date. To conclude, 68Ga-FAPI PET/MR aids in primary tumor determination and tumor burden assessment and provides a guide for the management of late-stage HGSOC patients.

高级别浆液性卵巢癌(HGSOC)是上皮性卵巢癌中最常见的一种,具有起病隐匿、生长迅速、浸润扩散等特点。在此,我们报告了通过 68Ga-FAPI PET/MR 扫描对一名有子宫切除史的 53 岁患者的诊断和治疗。患者最初因左侧颈部肿块就诊于当地医院,活检提示为转移性癌症。盆腔超声检查发现两个不规则肿块。入院后进行了肿瘤标志物检查、活检病理会诊和 68Ga-FAPI PET/MR 扫描。肿块活检提示为分化较差的腺癌,CA125升高至530.6 U/ml。68Ga-FAPI PET/MR 扫描显示多个异常淋巴结和两个软组织肿块,肿块边界呈分散限制性,内部信号不均匀,盆腔内的 T1 和 T2 信号略有拉长,表明盆腔肿块可能是原发病灶。患者接受了细胞切除手术,包括双侧附件切除术、卵巢切除术和阑尾切除术。术后病理结果显示,左右侧 HGSOC 均有左侧输卵管受侵。患者完成了六个疗程的一线化疗,至今已14个月无进展。总之,68Ga-FAPI PET/MR 有助于原发肿瘤的确定和肿瘤负荷的评估,并为晚期 HGSOC 患者的治疗提供指导。
{"title":"Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by <sup>68</sup>Ga-FAPI PET/MR scan.","authors":"Mengna Zhu, Si Sun, Lin Huang, Mengqing Chen, Jing Cai, Zehua Wang, Liqiong Cai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer with insidious onset, rapid growth, and invasive spread. Here, we reported the diagnosis and treatment of a 53-year-old patient with a history of hysterectomy aided by the <sup>68</sup>Ga-FAPI PET/MR scan. The patient was first presented to the local hospital with a lump on the left side of the neck with a biopsy suggesting metastatic cancer. Pelvic ultrasonography revealed two irregular masses. After admission, tumor markers, pathology consultation of the biopsy, and the <sup>68</sup>Ga-FAPI PET/MR scan were administered. The biopsy of the lump suggested poorly differentiated adenocarcinoma and CA125 was elevated at 530.6 U/ml. The <sup>68</sup>Ga-FAPI PET/MR scan showed several abnormal lymph nodes and two soft tissue masses with borders of dispersed restriction displaying internally uneven signals depicted by slightly elongated T1 and T2 signals within the pelvic cavity suggesting that pelvic mass could be the primary lesion. The patient received cytoreductive surgery including bilateral adnexectomy, omentectomy, and appendectomy. Post-surgical pathology suggested left and right HGSOC with left fallopian tube invasion. The patient completed six courses of first-line chemotherapy and remained progression-free for 14 months up to date. To conclude, <sup>68</sup>Ga-FAPI PET/MR aids in primary tumor determination and tumor burden assessment and provides a guide for the management of late-stage HGSOC patients.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro evaluation of PET radiotracers reflecting multidimensionality of Alzheimer's disease: building more roadmaps for clinical translation. 对反映阿尔茨海默病多维性的 PET 放射性同位素进行体外评估:为临床转化绘制更多路线图。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Yingfang He, Fang Xie

In the current issue of American Journal of Nuclear Medicine and Molecular Imaging, Vasdev et al. presented a work entitled "In Vitro Evaluation of PET Radiotracers for Imaging Synaptic Density, the Acetylcholine Transporter, AMPA-tarp-γ8 and Muscarinic M4 receptors in Alzheimer's disease". In which, in vitro autoradiography studies using radioligands were employed as a valuable tool to gain more insights for potential clinical translation. In this invited perspective, we would like to briefly introduce the current state of AD diagnosis, especially PET imaging on synapse, and highlight the advances of PET imaging in pre-clinic and clinic that might assist on precise therapy in the future.

在本期《美国核医学与分子成像杂志》(American Journal of Nuclear Medicine and Molecular Imaging)上,Vasdev 等人发表了一篇题为 "体外评估 PET 放射性标记物在阿尔茨海默病中的突触密度、乙酰胆碱转运体、AMPA-tarp-γ8 和 M4 肌卡宁受体成像 "的论文。其中,利用放射配体进行的体外自显影研究是一种宝贵的工具,可为潜在的临床转化提供更多的见解。在这篇特邀论文中,我们想简要介绍一下目前的阿尔茨海默病诊断状况,尤其是突触的 PET 成像,并强调 PET 成像在临床前和临床中的进展,这可能有助于未来的精确治疗。
{"title":"In vitro evaluation of PET radiotracers reflecting multidimensionality of Alzheimer's disease: building more roadmaps for clinical translation.","authors":"Yingfang He, Fang Xie","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the current issue of American Journal of Nuclear Medicine and Molecular Imaging, Vasdev et al. presented a work entitled \"In Vitro Evaluation of PET Radiotracers for Imaging Synaptic Density, the Acetylcholine Transporter, AMPA-tarp-γ8 and Muscarinic M4 receptors in Alzheimer's disease\". In which, in vitro autoradiography studies using radioligands were employed as a valuable tool to gain more insights for potential clinical translation. In this invited perspective, we would like to briefly introduce the current state of AD diagnosis, especially PET imaging on synapse, and highlight the advances of PET imaging in pre-clinic and clinic that might assist on precise therapy in the future.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of factors affecting CT attenuation and glucose metabolism of bone marrow as seen on PET/CT scans. 研究 PET/CT 扫描显示的影响 CT 衰减和骨髓葡萄糖代谢的因素。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Shiro Ishii, Ryo Yamakuni, Shigeyasu Sugawara, Junko Hara, Yoshiki Endo, Hirotoshi Hotsumi, Mahori Hiruta, Honami Kobiyama, Yuki Yaginuma, Kenji Fukushima, Hiroshi Ito

The aim of this study is to determine the factors affecting the CT attenuation of bone marrow, and its correlation with 18F-FDG uptake. The mean standardized uptake value (SUV) of vertebral bone marrow (Vertebral-SUV) and femoral bone marrow (Femoral-SUV) as well as CT number of bone marrow (BM-CT number) were measured in 243 patients who had undergone 18F-FDG PET/CT. The correlations among BM-CT number, Femoral-SUV, and Vertebral-SUV were investigated. The relationships of Femoral-SUV, Vertebral-SUV, and BM-CT number with blood parameters, age, blood sugar, and body weight were analyzed by correlation and multi-regression analyses. The Mann-Whitney U test and chi-square test and Binomial logistic analysis were used to examine the relationships between high BM-CT number (≥ 0 HU) and the above parameters. Significant correlations were observed between: BM-CT number and Femoral-SUV (r = 0.73, P < 0.01); Vertebral-SUV and Femoral-SUV (r = 0.78, P < 0.01); and BM-CT number and Vertebral-SUV (r = 0.52, P < 0.01). BM-CT number was correlated with patients' age in both univariable (r = -0.27) and multivariable analyses (β = -0.20). Positive BM-CT number correlated with WBC in both univariable (P = 0.04) and multivariable (P < 0.01) analyses. Bone marrow glucose metabolism had a tendency to decrease with age, was increased in patients with elevated CRP. In conclusion, CT attenuation of bone marrow correlated well with bone marrow metabolism and also tended to decrease with age. High bone marrow attenuation (≥ 0 HU) could predict elevated serum WBC.

本研究旨在确定影响骨髓 CT 衰减的因素及其与 18F-FDG 摄取的相关性。研究测量了 243 名接受 18F-FDG PET/CT 的患者的椎骨骨髓(Vertebral-SUV)和股骨髓(Femoral-SUV)的平均标准化摄取值(SUV)以及骨髓 CT 数量(BM-CT 数量)。研究了骨髓 CT 数、股骨-SUV 和椎骨-SUV 之间的相关性。通过相关分析和多元回归分析,分析了股骨-SUV、椎骨-SUV 和 BM-CT 数量与血液参数、年龄、血糖和体重的关系。采用曼-惠特尼 U 检验和卡方检验以及二项式逻辑分析来检验高 BM-CT 数量(≥ 0 HU)与上述参数之间的关系。结果表明BM-CT数量与股骨-SUV(r = 0.73,P < 0.01);椎骨-SUV与股骨-SUV(r = 0.78,P < 0.01);BM-CT数量与椎骨-SUV(r = 0.52,P < 0.01)。在单变量分析(r = -0.27)和多变量分析(β = -0.20)中,BM-CT 数量与患者年龄相关。在单变量(P = 0.04)和多变量(P < 0.01)分析中,BM-CT 阳性数量与白细胞相关。骨髓葡萄糖代谢随年龄增长呈下降趋势,CRP升高的患者骨髓葡萄糖代谢增加。总之,骨髓 CT 的衰减与骨髓代谢有很好的相关性,也有随年龄增长而降低的趋势。高骨髓衰减(≥ 0 HU)可预测血清白细胞升高。
{"title":"Investigation of factors affecting CT attenuation and glucose metabolism of bone marrow as seen on PET/CT scans.","authors":"Shiro Ishii, Ryo Yamakuni, Shigeyasu Sugawara, Junko Hara, Yoshiki Endo, Hirotoshi Hotsumi, Mahori Hiruta, Honami Kobiyama, Yuki Yaginuma, Kenji Fukushima, Hiroshi Ito","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study is to determine the factors affecting the CT attenuation of bone marrow, and its correlation with <sup>18</sup>F-FDG uptake. The mean standardized uptake value (SUV) of vertebral bone marrow (Vertebral-SUV) and femoral bone marrow (Femoral-SUV) as well as CT number of bone marrow (BM-CT number) were measured in 243 patients who had undergone <sup>18</sup>F-FDG PET/CT. The correlations among BM-CT number, Femoral-SUV, and Vertebral-SUV were investigated. The relationships of Femoral-SUV, Vertebral-SUV, and BM-CT number with blood parameters, age, blood sugar, and body weight were analyzed by correlation and multi-regression analyses. The Mann-Whitney U test and chi-square test and Binomial logistic analysis were used to examine the relationships between high BM-CT number (≥ 0 HU) and the above parameters. Significant correlations were observed between: BM-CT number and Femoral-SUV (r = 0.73, P < 0.01); Vertebral-SUV and Femoral-SUV (r = 0.78, P < 0.01); and BM-CT number and Vertebral-SUV (r = 0.52, P < 0.01). BM-CT number was correlated with patients' age in both univariable (r = -0.27) and multivariable analyses (β = -0.20). Positive BM-CT number correlated with WBC in both univariable (P = 0.04) and multivariable (P < 0.01) analyses. Bone marrow glucose metabolism had a tendency to decrease with age, was increased in patients with elevated CRP. In conclusion, CT attenuation of bone marrow correlated well with bone marrow metabolism and also tended to decrease with age. High bone marrow attenuation (≥ 0 HU) could predict elevated serum WBC.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab. 用 64Cu 标记的 Durvalumab 对肿瘤 PD-L1 表达进行无创 PET 成像。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Sara Malih, Wilson Lin, Zhongmin Tang, Molly C DeLuca, Jonathan W Engle, Behrouz Alirezapour, Weibo Cai, Mohammad J Rasaee

Breast cancer (BrCa) ranks as the most prevalent malignant neoplasm affecting women worldwide. The expression of programmed death-ligand 1 (PD-L1) in BrCa has recently emerged as a biomarker for immunotherapy response, but traditional immunohistochemistry (IHC)-based methods are hindered by spatial and temporal heterogeneity. Noninvasive and quantitative PD-L1 imaging using appropriate radiotracers can serve to determine PD-L1 expression in tumors. This study aims to demonstrate the viability of PET imaging with 64Cu-labeled Durvalumab (abbreviated as Durva) to assess PD-L1 expression using a murine xenograft model of breast cancer. Durvalumab, a human IgG1 monoclonal antibody against PD-L1, was assessed for specificity in vitro in two cancer cell lines (MDA-MB-231 triple-negative breast cancer cell line and AsPC-1 pancreatic cancer cell line) with positive and negative PD-L1 expression by flow cytometry. Next, we performed the in vivo evaluation of 64Cu-NOTA-Durva in murine models of human breast cancer by PET imaging and ex vivo biodistribution. Additionally, mice bearing AsPC-1 tumors were employed as a negative control. Tumor uptake was quantified based on a 3D region-of-interest (ROI) analysis of the PET images and ex vivo biodistribution measurements, and the results were compared against conventional IHC testing. The radiotracer uptake was evident in MDA-MB-231 tumors and showed minimal nonspecific binding, corroborating IHC-derived results. The results of the biodistribution showed that the MDA-MB-231 tumor uptake of 64Cu-NOTA-Durva was much higher than 64Cu-NOTA-IgG (a nonspecific radiolabeled IgG). In Conclusion, 64Cu-labeled Durvalumab PET/CT imaging offers a promising, noninvasive approach to evaluate tumor PD-L1 expression.

乳腺癌(BrCa)是全球女性发病率最高的恶性肿瘤。最近,程序性死亡配体 1(PD-L1)在乳腺癌中的表达已成为免疫疗法反应的生物标志物,但基于免疫组化(IHC)的传统方法受到空间和时间异质性的阻碍。使用适当的放射性同位素进行无创和定量的 PD-L1 成像可用于确定肿瘤中的 PD-L1 表达。本研究旨在证明使用 64Cu 标记的 Durvalumab(缩写为 Durva)进行 PET 成像的可行性,利用小鼠乳腺癌异种移植模型评估 PD-L1 的表达。Durvalumab是一种针对PD-L1的人类IgG1单克隆抗体,我们通过流式细胞术在体外对两种PD-L1表达阳性和阴性的癌细胞系(MDA-MB-231三阴性乳腺癌细胞系和AsPC-1胰腺癌细胞系)进行了特异性评估。接下来,我们在人类乳腺癌小鼠模型中通过 PET 成像和体内外生物分布对 64Cu-NOTA-Durva 进行了体内评估。此外,我们还将携带 AsPC-1 肿瘤的小鼠作为阴性对照。根据 PET 图像的三维感兴趣区(ROI)分析和体内外生物分布测量对肿瘤摄取进行了量化,并将结果与传统的 IHC 检测进行了比较。MDA-MB-231肿瘤对放射性示踪剂的摄取非常明显,非特异性结合极少,证实了IHC得出的结果。生物分布结果显示,MDA-MB-231 肿瘤对 64Cu-NOTA-Durva 的摄取远高于 64Cu-NOTA-IgG(一种非特异性放射性标记的 IgG)。总之,64Cu标记的Durvalumab PET/CT成像为评估肿瘤PD-L1的表达提供了一种前景广阔的无创方法。
{"title":"Noninvasive PET imaging of tumor PD-L1 expression with <sup>64</sup>Cu-labeled Durvalumab.","authors":"Sara Malih, Wilson Lin, Zhongmin Tang, Molly C DeLuca, Jonathan W Engle, Behrouz Alirezapour, Weibo Cai, Mohammad J Rasaee","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast cancer (BrCa) ranks as the most prevalent malignant neoplasm affecting women worldwide. The expression of programmed death-ligand 1 (PD-L1) in BrCa has recently emerged as a biomarker for immunotherapy response, but traditional immunohistochemistry (IHC)-based methods are hindered by spatial and temporal heterogeneity. Noninvasive and quantitative PD-L1 imaging using appropriate radiotracers can serve to determine PD-L1 expression in tumors. This study aims to demonstrate the viability of PET imaging with <sup>64</sup>Cu-labeled Durvalumab (abbreviated as Durva) to assess PD-L1 expression using a murine xenograft model of breast cancer. Durvalumab, a human IgG1 monoclonal antibody against PD-L1, was assessed for specificity <i>in vitro</i> in two cancer cell lines (MDA-MB-231 triple-negative breast cancer cell line and AsPC-1 pancreatic cancer cell line) with positive and negative PD-L1 expression by flow cytometry. Next, we performed the <i>in vivo</i> evaluation of <sup>64</sup>Cu-NOTA-Durva in murine models of human breast cancer by PET imaging and <i>ex vivo</i> biodistribution. Additionally, mice bearing AsPC-1 tumors were employed as a negative control. Tumor uptake was quantified based on a 3D region-of-interest (ROI) analysis of the PET images and <i>ex vivo biodistribution</i> measurements, and the results were compared against conventional IHC testing. The radiotracer uptake was evident in MDA-MB-231 tumors and showed minimal nonspecific binding, corroborating IHC-derived results. The results of the biodistribution showed that the MDA-MB-231 tumor uptake of <sup>64</sup>Cu-NOTA-Durva was much higher than <sup>64</sup>Cu-NOTA-IgG (a nonspecific radiolabeled IgG). In Conclusion, <sup>64</sup>Cu-labeled Durvalumab PET/CT imaging offers a promising, noninvasive approach to evaluate tumor PD-L1 expression.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two decades of [11C]PiB synthesis, 2003-2023: a review. 2003-2023 年[11C]PiB 合成二十年:回顾。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Paul Josef Myburgh, Kiran Kumar Solingapuram Sai

Because carbon-11 (11C) radiotracers cannot be shipped over long distances, their use in routine positron emission tomography (PET) studies is dependent on the production capabilities of individual radiochemistry laboratories. Since 2003, 11C-labeled Pittsburgh compound B ([11C]PiB) has been the gold standard PET radiotracer for in vivo imaging of amyloid β (Aβ) plaques. For more than two decades, researchers have been working to develop faster, higher-yielding, more robust, and optimized production methods with higher radiochemical yields for various imaging applications. This review evaluates progress in [11C]PiB radiochemistry. An introductory overview assesses how it has been applied in clinical neurologic imaging research. We examine the varying approaches reported for radiolabeling, purification, extraction, and formulation. Further considerations for QC methods, regulatory considerations, and optimizations were also discussed.

由于碳-11(11C)放射性示踪剂无法远距离运输,因此其在常规正电子发射断层扫描(PET)研究中的应用取决于各个放射化学实验室的生产能力。自 2003 年以来,11C 标记的匹兹堡化合物 B([11C]PiB)一直是淀粉样β(Aβ)斑块体内成像的黄金标准 PET 放射性示踪剂。二十多年来,研究人员一直致力于为各种成像应用开发更快、更高产、更稳健、更优化的生产方法,以及更高的放射化学产率。本综述评估了 [11C]PiB 放射化学的进展。介绍性概述评估了其在临床神经成像研究中的应用情况。我们研究了已报道的放射标记、纯化、提取和配制的不同方法。此外,还讨论了质量控制方法、监管注意事项和优化方面的进一步考虑。
{"title":"Two decades of [<sup>11</sup>C]PiB synthesis, 2003-2023: a review.","authors":"Paul Josef Myburgh, Kiran Kumar Solingapuram Sai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Because carbon-11 (<sup>11</sup>C) radiotracers cannot be shipped over long distances, their use in routine positron emission tomography (PET) studies is dependent on the production capabilities of individual radiochemistry laboratories. Since 2003, <sup>11</sup>C-labeled Pittsburgh compound B ([<sup>11</sup>C]PiB) has been the gold standard PET radiotracer for <i>in vivo</i> imaging of amyloid β (Aβ) plaques. For more than two decades, researchers have been working to develop faster, higher-yielding, more robust, and optimized production methods with higher radiochemical yields for various imaging applications. This review evaluates progress in [<sup>11</sup>C]PiB radiochemistry. An introductory overview assesses how it has been applied in clinical neurologic imaging research. We examine the varying approaches reported for radiolabeling, purification, extraction, and formulation. Further considerations for QC methods, regulatory considerations, and optimizations were also discussed.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer. 分子成像揭示肿瘤细胞和肿瘤基质的异质性进展:FDG PET 和 FAPI PET 在诊断 PSMA 阴性进展期前列腺癌骨转移中的应用。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Lizhi Zhu, Peng Chen, Zhongqiu Guo, Fangdu Li, Xiu Luo, Xia Du, Liying Zhang, Changjing Zuo, Xiao Li

Tumors are often with complex and heterogeneous biological processes, such as glycometabolism and fibrosis, which are the main biochemical pathways that determine therapeutic effects. Specifically, this study aims to assess the diagnosing performance of 18F-FDG and 68Ga-FAPI-04 PET for different stages of progressive bone metastases with PSMA-negative pathology. Bone metastatic mouse model of prostate cancer was constructed via intra-bone injection of PSMA-negative prostate cancer PC3 cells. Cellular uptakes of 18F-FDG and 68Ga-FAPI-04 were separately performed on PC3, NIH-3T3 (FAP-positive) and a mixture. 68Ga-PSMA-11, 18F-FDG and 68Ga-FAPI-04 PET/CT imaging were performed at 2, 4 weeks after tumor cell transplantation. Furthermore, PSMA and FAP expression in bone metastases were assessed by immunohistochemistry, and then compared with the imageological findings. On the cellular level, the independent tracer uptake on the basis of glycometabolism and fibrosis was observed. For animal imaging, 68Ga-PSMA-11 imaging showed weak or absent tracer uptake in PSMA-negative bone metastatic lesions. In contrast, 68Ga-FAPI-04 PET of bone metastases had a higher uptake and tumor-to-muscle (T/M) ratio than 18F-FDG PET that was relative steady during the observation, but T/M ratio of fibrosis gradually decreased with increasing tumor growth, which ranged from 5.11 ± 1.26 at 2 weeks to 3.54 ± 0.23 at 4 weeks, revealing the delayed formation of tumor stroma in rapid proliferation. In addition, PET imaging results were corroborated by immunohistochemical assessment. In conclusion, molecular imaging approach revealed the heterogeneous progression of tumor cells and tumor stroma of bone metastasis of prostate cancer, and further confirming the necessity of multi-molecular imaging in cancer imaging.

肿瘤通常具有复杂和异质性的生物过程,如糖代谢和纤维化,这是决定治疗效果的主要生化途径。具体而言,本研究旨在评估 18F-FDG 和 68Ga-FAPI-04 PET 对 PSMA 阴性病理的不同进展期骨转移瘤的诊断性能。通过骨内注射 PSMA 阴性的前列腺癌 PC3 细胞,构建了前列腺癌骨转移小鼠模型。分别对 PC3、NIH-3T3(FAP 阳性)和混合物进行了 18F-FDG 和 68Ga-FAPI-04 的细胞摄取。68Ga-PSMA-11、18F-FDG 和 68Ga-FAPI-04 PET/CT 成像分别在肿瘤细胞移植后 2 周和 4 周进行。此外,还通过免疫组化方法评估了骨转移灶中 PSMA 和 FAP 的表达,并与影像学结果进行了比较。在细胞水平上,观察到糖代谢和纤维化对示踪剂的独立吸收。在动物成像方面,68Ga-PSMA-11成像显示,在PSMA阴性的骨转移病灶中示踪剂摄取很弱或没有摄取。相比之下,68Ga-FAPI-04 PET 对骨转移灶的摄取量和肿瘤与肌肉(T/M)比值均高于 18F-FDG PET,且在观察期间相对稳定,但纤维化的 T/M 比值随肿瘤生长而逐渐降低,从 2 周时的 5.11 ± 1.26 降至 4 周时的 3.54 ± 0.23,显示肿瘤在快速增殖过程中基质形成延迟。此外,免疫组化评估也证实了 PET 成像的结果。总之,分子成像方法揭示了前列腺癌骨转移的肿瘤细胞和肿瘤基质的异质性进展,进一步证实了多分子成像在癌症成像中的必要性。
{"title":"Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.","authors":"Lizhi Zhu, Peng Chen, Zhongqiu Guo, Fangdu Li, Xiu Luo, Xia Du, Liying Zhang, Changjing Zuo, Xiao Li","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tumors are often with complex and heterogeneous biological processes, such as glycometabolism and fibrosis, which are the main biochemical pathways that determine therapeutic effects. Specifically, this study aims to assess the diagnosing performance of <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-04 PET for different stages of progressive bone metastases with PSMA-negative pathology. Bone metastatic mouse model of prostate cancer was constructed via intra-bone injection of PSMA-negative prostate cancer PC3 cells. Cellular uptakes of <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-04 were separately performed on PC3, NIH-3T3 (FAP-positive) and a mixture. <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI-04 PET/CT imaging were performed at 2, 4 weeks after tumor cell transplantation. Furthermore, PSMA and FAP expression in bone metastases were assessed by immunohistochemistry, and then compared with the imageological findings. On the cellular level, the independent tracer uptake on the basis of glycometabolism and fibrosis was observed. For animal imaging, <sup>68</sup>Ga-PSMA-11 imaging showed weak or absent tracer uptake in PSMA-negative bone metastatic lesions. In contrast, <sup>68</sup>Ga-FAPI-04 PET of bone metastases had a higher uptake and tumor-to-muscle (T/M) ratio than <sup>18</sup>F-FDG PET that was relative steady during the observation, but T/M ratio of fibrosis gradually decreased with increasing tumor growth, which ranged from 5.11 ± 1.26 at 2 weeks to 3.54 ± 0.23 at 4 weeks, revealing the delayed formation of tumor stroma in rapid proliferation. In addition, PET imaging results were corroborated by immunohistochemical assessment. In conclusion, molecular imaging approach revealed the heterogeneous progression of tumor cells and tumor stroma of bone metastasis of prostate cancer, and further confirming the necessity of multi-molecular imaging in cancer imaging.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unexpected 99mTc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases. 有淋巴结转移的分化型甲状腺癌患者淋巴结转移灶的99m锝-过硫酸盐嗜性可预示对放射性碘治疗的更好反应。
IF 2.5 Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Jie Liu, Xin Li, Linfa Li, Yuhua Yin, Hu Cai, Heqing Yi

Objective: To investigate the value of 99mTc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake 99mTc-pertechnetate, especially the predictive value to their response to radioiodine-131 (131I) therapy.

Methods: This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake 99mTc-pertechnetate, the patients were grouped as the 99mTc-pertechnetate-avid (n=88) vs. 99mTc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias.

Results: In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with 99mTc-pertechnetate-avid LNM, 664 with 99mTc-pertechnetate-non-avid LNM). Patients' age, initial 131I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients (99mTc-pertechnetate-avid group, n=83; 99mTc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the 99mTc-pertechnetate-avid group and 158/280 (56.4%) in the 99mTc-pertechnetate-non-avid group had two or more 131I treatments. The nsTg and the percentage of changes in ssTg between the 99mTc-pertechnetate-avid and 99mTc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), p=0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), p < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial 131I treatment activity, and 131I treatment frequency) after PSM (all p > 0.05).

Conclusion: In patients with DTC and LNM, LNM uptake of 99mTc-pertechnetate is a rare phenomenon. Patients with 99mTc-pertechnetate-avid LNMs were more likely to benefit from 131I therapy, even after adjustment for age, 131I treatment frequency, and initial 131I activity.

目的探讨99m锝-过硫酸盐扫描在术后分化型甲状腺癌(DTC)淋巴结(LNM)转移(LNM)患者摄取99m锝-过硫酸盐的价值,尤其是对其放射性碘-131(131I)治疗反应的预测价值:这项回顾性研究收集了2012年5月至2017年12月期间在浙江省肿瘤医院接受治疗的752例DTC和LNM患者。根据LNM摄取99m锝-pertechnetate的能力,将患者分为99m锝-pertechnetate-avid组(n=88)和99m锝-pertechnetate-non-avid组(n=664)。并按1:4的比例进行倾向评分匹配(PSM),以减少混杂偏差:在PSM分析中,1:4配对队列由752名患者组成(88名99m锝-过硫酸盐-亲和性LNM患者,664名99m锝-过硫酸盐-非亲和性LNM患者)。患者的年龄、初始 131I 活性和碘治疗频率被列为协变量。经过 PSM 分析,363 名患者(99m锝-过硫酸盐-亲和组,n=83;99m锝-过硫酸盐-非亲和组,n=280)成功配对。在363名PSM匹配患者中,99m锝-过硫酸盐-avid组48/83(57.8%)人和99m锝-过硫酸盐-non-avid组158/280(56.4%)人接受过两次或两次以上的131I治疗。99mTc-pertechnetate-avid 组和 99mTc-pertechnetate-non-avid 组的 nsTg 和 ssTg 变化百分比有显著差异(分别为 [0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), p=0.018] 和 [-88% (-98%, -50%) vs. -66% (-86%, -30%), p < 0.001])。PSM 后,两组患者在其他参数(年龄、病理类型、远处转移、随访时间、AJCC TNM 分期、初始 131I 治疗活性和 131I 治疗频率)方面无明显差异(均 p > 0.05):结论:在 DTC 和 LNM 患者中,LNM 摄取 99mTc-pertechnetate 是一种罕见现象。即使对年龄、131I 治疗频率和初始 131I 活性进行了调整,具有 99mTc-pertechnetate-avid LNM 的患者也更有可能从 131I 治疗中获益。
{"title":"Unexpected <sup>99m</sup>Tc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases.","authors":"Jie Liu, Xin Li, Linfa Li, Yuhua Yin, Hu Cai, Heqing Yi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the value of <sup>99m</sup>Tc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake <sup>99m</sup>Tc-pertechnetate, especially the predictive value to their response to radioiodine-131 (<sup>131</sup>I) therapy.</p><p><strong>Methods: </strong>This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake <sup>99m</sup>Tc-pertechnetate, the patients were grouped as the <sup>99m</sup>Tc-pertechnetate-avid (n=88) vs. <sup>99m</sup>Tc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias.</p><p><strong>Results: </strong>In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with <sup>99m</sup>Tc-pertechnetate-avid LNM, 664 with <sup>99m</sup>Tc-pertechnetate-non-avid LNM). Patients' age, initial <sup>131</sup>I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients (<sup>99m</sup>Tc-pertechnetate-avid group, n=83; <sup>99m</sup>Tc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the <sup>99m</sup>Tc-pertechnetate-avid group and 158/280 (56.4%) in the <sup>99m</sup>Tc-pertechnetate-non-avid group had two or more <sup>131</sup>I treatments. The nsTg and the percentage of changes in ssTg between the <sup>99m</sup>Tc-pertechnetate-avid and <sup>99m</sup>Tc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), <i>p</i>=0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), <i>p</i> < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial <sup>131</sup>I treatment activity, and <sup>131</sup>I treatment frequency) after PSM (all <i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>In patients with DTC and LNM, LNM uptake of <sup>99m</sup>Tc-pertechnetate is a rare phenomenon. Patients with <sup>99m</sup>Tc-pertechnetate-avid LNMs were more likely to benefit from <sup>131</sup>I therapy, even after adjustment for age, <sup>131</sup>I treatment frequency, and initial <sup>131</sup>I activity.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma: a comprehensive evaluation method. 18F-FDG PET/CT 在结外自然杀伤/T 细胞淋巴瘤中的应用:一种综合评估方法。
IF 2.5 Pub Date : 2023-12-25 eCollection Date: 2023-01-01
Xiaoyue Zhang, Wenpeng Huang, Yongkang Qiu, Zhao Chen, Lele Song, Qi Yang, Lei Kang

Extranodal NK/T-cell lymphoma (ENKTL) is an uncommon subtype of non-Hodgkin's lymphoma that is closely related to Epstein-Barr virus (EBV) infection. ENKTL exhibits distinctive clinicopathological features among lymphomas and has poor overall survival in the absence of effective treatment. The timely and accurate diagnosis of ENKTL is crucial for effective treatment and a positive prognosis. 18F-Fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) has emerged as an invaluable diagnostic modality for staging, curative effect evaluation, and prognosis analysis in ENKTL. We herein provide a comprehensive overview of the advances in the application of 18F-FDG PET/CT in patients with ENKTL.

结节外NK/T细胞淋巴瘤(ENKTL)是非霍奇金淋巴瘤中一种不常见的亚型,与爱泼斯坦-巴氏病毒(EBV)感染密切相关。ENKTL在淋巴瘤中表现出独特的临床病理特征,在缺乏有效治疗的情况下,总生存率较低。及时准确地诊断ENKTL对有效治疗和良好预后至关重要。18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)已成为ENKTL分期、疗效评估和预后分析的重要诊断方式。我们在此全面概述 18F-FDG PET/CT 在 ENKTL 患者中的应用进展。
{"title":"<sup>18</sup>F-FDG PET/CT in extranodal natural killer/T-cell lymphoma: a comprehensive evaluation method.","authors":"Xiaoyue Zhang, Wenpeng Huang, Yongkang Qiu, Zhao Chen, Lele Song, Qi Yang, Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extranodal NK/T-cell lymphoma (ENKTL) is an uncommon subtype of non-Hodgkin's lymphoma that is closely related to Epstein-Barr virus (EBV) infection. ENKTL exhibits distinctive clinicopathological features among lymphomas and has poor overall survival in the absence of effective treatment. The timely and accurate diagnosis of ENKTL is crucial for effective treatment and a positive prognosis. <sup>18</sup>F-Fluorodeoxyglucose-positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) has emerged as an invaluable diagnostic modality for staging, curative effect evaluation, and prognosis analysis in ENKTL. We herein provide a comprehensive overview of the advances in the application of <sup>18</sup>F-FDG PET/CT in patients with ENKTL.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of nuclear medicine and molecular imaging
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1